Antibiotic Use in Sub-Saharan Africa: Challenges and Strategies

By Crystal Lubbe

October 29, 2024

The article titled “Antibiotic prescription sources and use among under-5 children with fever/cough in sub-Saharan Africa” provides a critical analysis of antibiotic use and prescription sources for children under 5 with fever or cough in sub-Saharan Africa (SSA). In particular, this analysis sheds light on the significant issue of antibiotic misuse, thereby emphasising the necessity for appropriate interventions.

Methodology

The study used data from the Demographic and Health Surveys (DHS) from 2006 to 2021, covering 37 SSA countries and including 18,866 children under 5 with fever or cough.

Main Findings

Overall, the majority of children received antibiotics from unqualified sources, which highlights a significant issue with inappropriate use in the region. Moreover, the study identified that children with formally educated mothers were more likely to receive antibiotics from qualified sources. This finding stressed the vital role of maternal education in improving antibiotic prescription sources.

Implications and Recommendations

Consequently, these findings stress the need to address healthcare disparities, enhance access to qualified providers, and promote maternal education, to ensure proper antibiotic use. Moreover, there is an urgency for targeted interventions and policies to optimise antibiotic prescribing practices and combat AMR in sub-Saharan Africa.

Antimicrobial Resistance

The World Health Organization’s 2022 report highlights AMR as a leading cause of death, attributing 5 million deaths in 2019 to bacterial AMR. The United Nations warns that AMR can lead to 10 million deaths annually by 2050, resulting in severe economic consequences.

Gap in Existing Literature

The study addresses a gap by focusing on children under 5 with fever or cough in SSA. This population has often been overlooked in research, which typically focused on adults or limited simulations in a few countries.

Conclusion

The study offers insights into antibiotic prescription patterns and determinants for children under 5 in sub-Saharan Africa. This stresses the need for effective interventions to ensure proper antibiotic use and reduce antimicrobial resistance risks. Addressing these issues is vital for the health of children in the region.

Reference url

Recent Posts

TLX250-CDx imaging agent
      

Zircaix: A Potential Breakthrough in Kidney Cancer Diagnosis

🔍 Could a new imaging agent revolutionize kidney cancer diagnosis?

The FDA’s acceptance of the Biologics License Application for TLX250-CDx marks a significant milestone in the fight against clear cell renal cell carcinoma (ccRCC). This investigational PET imaging tool promises non-invasive, high-accuracy diagnostics, which could lead to improved patient outcomes and better-targeted treatment plans.

Curious about its potential impact on healthcare and market dynamics? Dive into the full article to learn more!

#SyenzaNews #medicalimaging #oncology #HealthcareInnovation

personalized cancer vaccine
         

Personalized Cancer Vaccine in High-Risk Kidney Cancer Patients

🌟 Could personalized cancer vaccines be the future of cancer treatment?

A recent phase I clinical trial has shown promising results for a personalized cancer vaccine in patients with high-risk clear cell renal cell carcinoma (RCC). All participants developed immune responses, and notably, none experienced recurrence at a median follow-up of over 40 months! With a favorable safety profile, this approach may pave the way for more effective adjuvant therapies in oncology.

Jump into the full findings and see how this advancement could change the landscape of cancer treatment!

#SyenzaNews #oncology #biotechnology #innovation

ivonescimab clinical trials
    

Advancing Cancer Treatment: Ivonescimab’s Potential and Strategic Collaboration with Pfizer

🚀 Exciting news in the fight against cancer!

Summit Therapeutics has announced a groundbreaking collaboration with Pfizer to launch clinical trials for ivonescimab, an innovative PD-1/VEGF bispecific antibody. This partnership aims to evaluate the safety and effectiveness of ivonescimab in combination with Pfizer’s antibody drug conjugates across various solid tumors, including non-small cell lung cancer. 🌟

To learn more about this promising development and its potential impact on oncology treatment, dive into the full article!

#SyenzaNews #oncology #clinicaltrials #innovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.